Insmed provides business updates and near-term strategic outlook at 41st annual j.p. morgan healthcare conference

—topline data from phase 2 pk/pd study of brensocatib in patients with cystic fibrosis show clear dose response at all evaluated doses— —treatment discontinuation rate of 15% reported in postmarketing arise trial of arikayce® (amikacin liposome inhalation suspension) in frontline patients with mac lung disease—less than half that of pivotal trial in refractory patients— —blended, blinded event rate ranging from 1.12 to 1.15 events per patient per year reported in phase 3 aspen trial of brensocatib in patients with bronchiectasis, in line with expectations— —company expects to report 30% global revenue growth for arikayce in 2022 compared with 2021— —2023 global arikayce revenues expected to be between $285 million and $300 million— bridgewater, n.j. , jan. 6, 2023 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the company's four pillars and outlined its near-term strategic priorities.
INSM Ratings Summary
INSM Quant Ranking